Endometrial Cancer, Sentinel Lymph Node Detection
Conditions
Keywords
Endometrial cancer, Sentinel lymph node, Indocyanine green, Near infrared imaging
Brief summary
Patients with endometrial cancer who have planned robotic laparoscopic hysterectomy and full bilateral pelvic and para-aortic lymphadenectomy will receive injections of a fluorescent dye, Indocyanine green (ICG). ICG spreads through the lymphatic system, and will be visualized using near-infrared (NIR) imagers. Upon visualization of the path of the ICG, sentinel lymph nodes (SLNs), the first nodes to receive drainage from the primary tumor, will be identified. SLNs will be surgically removed and provided to Pathology for evaluation. Non-sentinel nodes will also be surgically removed, as is consistent with routine medical care for these patients, and given to Pathology for evaluation. A positive SLN may be the most accurate identifier of the extra-uterine spread of disease, and will provide information about the extent of surgical node removal necessary.
Interventions
PROCEDUREICG Dye
ICG Dye injections
Sponsors
Lahey Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Adult women patients (\>18 years of age and \<90 years of age) * Research authorization (consent) * Pre-operative diagnosis of clinical Stage 1 endometrial cancer * Pre-operative indications of grade 3 tumor, and/or tumor size greater than 2 cm in size * Scheduled and consented to undergo robotic hysterectomy and surgical staging, including bilateral pelvic and para-aortic lymphadenectomy
Exclusion criteria
* Severe coagulopathy or severe thrombocytopenia * Severe anemia * Severe cardio-pulmonary comorbidities demanding minimization of operative time * History of liver disease * Iodide allergy * Emergent operation * Additional surgical risk as determined during surgery at the discretion of the attending * Impaired capacity to make informed medical decisions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of sentinel lymph node(s) | Detection of SLNs will occur within surgery, on average this surgery will take 1-2 hours for each participant | The primary outcome is to determine whether sentinel lymph nodes (SLN) were accurately visualized using Indocyanine green (ICG) and near-infrared (NIR) imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison between sentinel node status for disease and non-sentinel node disease status | Following surgery and pathological evaluation of all removed nodes, up to 1 year | The pathological evaluation of the sentinel lymph nodes (positive or negative) will be compared to the status of the non-sentinel nodes removed to determine whether the sentinel nodes accurately reflected the same status as the non-sentinel nodes. |
Countries
United States
Outcome results
None listed